{"nctId":"NCT01850615","briefTitle":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","startDateStruct":{"date":"2013-09-23","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":323,"armGroups":[{"label":"FIAsp and basal insulin + metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Faster-acting insulin aspart","Drug: basal insulin"]},{"label":"Basal insulin + metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: basal insulin"]}],"interventions":[{"name":"Faster-acting insulin aspart","otherNames":["NN1218"]},{"name":"basal insulin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes (diagnosed clinically) for at least 6 months prior to the screening visit (Visit 1)\n* Current treatment with once daily insulin detemir, insulin glargine or human isophane insulin, NPH for at least 3 months prior to the screening visit (Visit 1)\n* Current treatment with a) metformin with unchanged dosing for at least 3 months prior to screening (visit 1). The metformin dose must be at least 1000 mg or b) metformin in combination with sulfonylurea (SU) or glinide or Dipeptidyl peptidase-IV inhibitors and/or alpha-glucosidase inhibitors (AGI) with unchanged dosing for at least 3 months prior to screening (visit 1). The metformin dose must be at least 1000 mg\n* HbA1c by central laboratory a) 7.5-9.5% (58 - 80 mmol/mol) (both inclusive) in the metformin group at the screening visit (Visit 1) or b) 7.5-9.0% (58 - 75 mmol/mol) (both inclusive) in the metformin + other oral antidiabetic drug (OAD) (sulphonylurea (SU), glinide, dipeptidyl peptidase-IV (DDP-IV) inhibitors, alpha-glucosidase inhibitors (AGI) combination group at the screening visit (Visit 1)\n* Body mass index (BMI) equal or less than 40.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Any use of bolus insulin, except short-term use due to intermittent illness (no longer than 14 days of consecutive treatment) and not within 3 months prior to the screening visit (Visit 1)\n* Use of Glucagon-like peptide-1 (GLP-1) agonists and/or Thiazolidinediones (TZD) within the last 3 months prior to screening (visit 1)\n* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening (Visit 1)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c","description":"For this endpoint, baseline (week 0) and week 18 data are presented, where week 18 data are the \"end of trial\" data containing last available measurements.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":"0.69"},{"groupId":"OG001","value":"7.92","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.78","spread":"0.92"},{"groupId":"OG001","value":"7.7","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Self-measured Plasma Glucose (SMPG) 7-point Profile: Post Prandial Plasma Glucose (PPG), Overall 2-hour Mean (of Breakfast, Lunch, Main Evening Meal)","description":"For this endpoint the \"end of trial\" data containing last available measurements are presented. PPG measurements were recorded by the subjects at 2 hours after each meal (breakfast, lunch and main evening meal) as part of three 7-point profiles (SMPG) prior to the visits. Individual mean meal PPG (post-breakfast, post-lunch, post-main evening meal) was derived from the three measurements.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"1.8"},{"groupId":"OG001","value":"9","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"1.9"},{"groupId":"OG001","value":"9.7","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1.9"},{"groupId":"OG001","value":"10.1","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Self-measured Plasma Glucose (SMPG) 7-point Profile: Prandial Plasma Glucose (PG) Increment, Overall 2-hour Mean (of Breakfast, Lunch, Main Evening Meal)","description":"For this endpoint the \"end of trial\" data containing last available measurements are presented. Prandial PG increment for each meal (breakfast, lunch, main evening meal) was derived from the 7-point profiles (SMPG) as the difference between the PPG value 2 hours after each meal and the PG value before each meal. Individual mean meal PPG (post-breakfast, post-lunch, post-main evening meal) was derived from the three measurements.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.8"},{"groupId":"OG001","value":"2.9","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.0"},{"groupId":"OG001","value":"1.8","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.7"},{"groupId":"OG001","value":"1.4","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"For this endpoint, baseline (week 0) and week 18 data are presented, where week 18 data are the \"end of trial\" data containing last available measurements.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":"16.2"},{"groupId":"OG001","value":"85.1","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":"16.9"},{"groupId":"OG001","value":"85.4","spread":"17.5"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Hypoglycaemic Episodes","description":"Plasma glucose (PG) was measured and recorded when a hypoglycaemic episode was suspected. All PG values â‰¤3.9 mmol/L (70 mg/dL) or \\>3.9 mmol/L (70 mg/dL) when they occurred in conjunction with hypoglycaemic symptoms were recorded by the subject. Numbers of treatment emergent hypoglycaemic episodes were recorded during 18 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1908","spread":null},{"groupId":"OG001","value":"347","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events","description":"All adverse events (AEs) described here refer to treatment emergent adverse events (TEAE). A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment, week 18.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":115},"commonTop":["Diarrhoea"]}}}